TAFINLAR (dabrafenib mesylate)


Drug overview for TAFINLAR (dabrafenib mesylate):

Generic name: DABRAFENIB MESYLATE (da-BRAF-e-nib)
Drug class: Antineoplastic - BRAF Kinase Inhibitors
Therapeutic class: Antineoplastics

Dabrafenib, an inhibitor of b-Raf serine-threonine kinase (BRAF) with V600E or V600K mutation, is an antineoplastic agent.

No enhanced Uses information available for this drug.
DRUG IMAGES
  • TAFINLAR 75 MG CAPSULE
    TAFINLAR 75 MG CAPSULE
The following indications for TAFINLAR (dabrafenib mesylate) have been approved by the FDA:

Indications:
Anaplastic thyroid carcinoma with BRAF V600E mutation
Low grade glioma with BRAF V600E mutation
Malignant melanoma with BRAF V600E mutation
Malignant melanoma with BRAF V600K mutation
Malignant solid tumor with BRAF V600E mutation
Non-small cell lung cancer with BRAF V600E mutation


Professional Synonyms:
Anaplastic thyroid cancer with BRAF V600E mutation
Melanoma with BRAF V600E genetic mutation
NSCLC with BRAF V600E mutation